Beleaguered Arrowhead 'Cautiously Optimistic' About RNAi Deal, Closes Calando's Lab
August 13, 2009
Beleaguered Arrowhead 'Cautiously Optimistic' About RNAi Deal, Closes Calando's Lab
Meanwhile, in a filing with the US Securities and Exchange Commission, Arrowhead warned that its fiscal 2009 operating losses and negative cash flows from operations "raises doubts about its ability to continue as a going concern over the next 12 months and beyond."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Arrowhead Reports Increased Fiscal Q4 Losses on Higher Expenses
December 22, 2011 / Gene Silencing News - Arrowhead Sees Partnership for Calando Subsidiary by Year End
August 19, 2010 / Gene Silencing News - Arrowhead Aims for HBV IND in Early 2013, Releases Preclinical Data from Program
May 10, 2012 / Gene Silencing News - Arrowhead Names HBV as Next RNAi Program While It Consolidates Operations
February 16, 2012 / Gene Silencing News - Arrowhead to Move Calando Cancer Drug into Phase Ib, Reports Fiscal Q3 Results
August 11, 2011 / Gene Silencing News